Business
Mesoblast reveals more COVID trials needed, shares tumble – Sydney Morning Herald
The Melbourne biotech has been advised by the US medicines regulator that it will need to run another trial of its COVID-19 treatment…
Stem cell treatments maker Mesoblast faces a new hurdle after the US medicines regulator told the company it would need to run another trial of its COVID-19 treatment before it could apply for emergency approvals.
Shares in the Melbourne biotech fell 15.9…
Continue Reading
-
Noosa News14 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General13 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
General15 hours agoCanberra man named as doctor accused of rape after suppression order lifted
-
Noosa News17 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate